Lilly Delivers Strong Third-Quart...(- Reported $4586.8 $3864.1 ...),Health

Reported $4,586.8 $3,864.1 19% $13,443.9 $11,445.7 17%

Total Sales -

Pro forma $4,586.8 $4,054.7 13% $13,516.6 $11,986.3 13%

(1) These amounts represent the reported Cialis sales in Lilly's financial

statements and do not include Cialis sales from the joint-venture

countries prior to the ICOS acquisition on January 29, 2007. Total

worldwide Cialis sales for the third quarter of 2007 of $311.4 million

represent 27 percent growth over the third quarter of 2006. September

year-to-date 2007 worldwide Cialis sales were $870.3 million and

represented 24 percent growth over the first nine months of 2006.

Significant Events Over the Last Three Months

-- The company today announced that it will acquire the exclusive rights

to teplizumab, a humanized anti-CD3 monoclonal antibody, from

MacroGenics, Inc. In addition, the two companies have entered into a

global strategic alliance to develop and commercialize teplizumab, as

well as other potential next-generation molecules for use in the

treatment of autoimmune diseases. Teplizumab is currently being studied

in the PROTEGE trial, a global pivotal Phase II/III clinical trial for

individuals with recent-onset type 1 diabetes.

-- The company submitted a supplemental new drug application to the U.S.

Food and Drug Administration for Cymbalta for the management of

fibromyalgia.

-- In September, the U.S. Food and Drug Administration approved Evista for

a new use to reduce the risk of invasive breast cancer in two

populations: postmenopausal women with osteoporosis and postmenopausal

women at high risk for invasive breast cancer.

-- The company submitted an application with the European Medicines Agency

for centralized review of Alimta, in combination with cisplatin
'/>"/>